Mitochondria (mt) play key roles in cellular energy production and cell death. Beta cell function is tightly linked to mitochondria, as both insulin synthesis and glucose stimulated insulin secretion require mitochondrial ATP production. In this context, reports of mitochondrial DNA (mtDNA) mutations associated with diabetes (T2D) pedigrees in humans account for up to 1% of human T2D. However, mutations in mtDNA are not commonly associated with autoimmune Type 1 diabetes (T1D), although a C to A transversion resulting in a leucine to methonine substitution in the mt-ND2 gene has been associated with protection from T1D in both an at risk human population and in crosses of the T1D-prone NOD with T1D-resistant ALR mice. The goal of this application is to understand how this single amino acid change modifies resistance to T1D. Genetic analysis of T1D susceptibility has focused attention on candidate genes controlling aberrant immune cell function with little focus on genes that may contribute susceptibility or resistance at the cell level. Pancreatic islets from the ALR mouse strain maintain an unusual genetic resistance to functional impairment and killing by autoimmune effectors. Our results have linked some of the ALR-derived T1D resistance to mt- Nd2a. While this allele does not prevent the development of spontaneous T1D when introgressed into the NOD genetic background, the ALR-derived genetic variant does in fact protect beta cells from destruction by cytotoxic T lymphocytes as well as combined cytokines. We have determined that this resistance stems from the inability of pro-apoptotic stress to induce mt reactive oxygen species. Our goal is to understand the role this gene plays in cell resistance to autoimmune killing.
In specific aim 1 we will determine the mechanism by which mt-Nd2a encoding beta cells resist destruction mediated by members of the Tumor Necrosis Factor Receptor family, TNFR1 and Fas.
Aim 2 will extend the studies to determine the mechanisms utilized by NIT-4 cells to avert lysis by CTL.
Specific aim 3 will use cybrid human beta cells to test if the human alleles of mt-ND2 alter the characteristics of human beta cell death. The studies, as proposed, will provide meaningful data on both the early apoptotic signals that results in beta cell death as well as insights into how ND2a protects beta cells.

Public Health Relevance

The genetics of susceptibility versus resistance to autoimmune T1D has primarily focused attention on candidate genes controlling function of the immune system rather than on the target beta cell. The assumption has been that insulin producing beta cells express a common repertoire of target antigens, yet play no other role in T1D pathogenesis than the corpse. In contrast to this commonly held view, our work has clearly shown that genetics play an important role in resistance of the target tissue to the autoimmune destruction leading to Type 1 Diabetes. The current proposal exploits a genetic difference that provides resistance to autoimmune-mediated destruction in both man and mouse. The goals of this proposal are to determine the mechanism this gene variant employs to prevent beta cell death and also to identify the early pro-death signals that occur in beta cells exposed to autoimmune effectors. Protective factors pancreatic islets can employ to ward off autoimmune-mediated destruction mechanisms have important ramifications for transplantation, stem cell engineering, and future genetic as well as pharmacological diabetes preventative therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
High Priority, Short Term Project Award (R56)
Project #
2R56DK074656-07
Application #
8331716
Study Section
Cellular Aspects of Diabetes and Obesity Study Section (CADO)
Program Officer
Spain, Lisa M
Project Start
2006-04-01
Project End
2012-05-31
Budget Start
2011-09-20
Budget End
2012-05-31
Support Year
7
Fiscal Year
2011
Total Cost
$106,913
Indirect Cost
Name
University of Florida
Department
Pathology
Type
Schools of Medicine
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Driver, John P; Racine, Jeremy J; Ye, Cheng et al. (2017) Interferon-? Limits Diabetogenic CD8+ T-Cell Effector Responses in Type 1 Diabetes. Diabetes 66:710-721
Whitener, Robert L; Gallo Knight, Lisa; Li, Jianwei et al. (2017) The Type 1 Diabetes-Resistance Locus Idd22 Controls Trafficking of Autoreactive CTLs into the Pancreatic Islets of NOD Mice. J Immunol 199:3991-4000
Cho, Joonseok; Zhang, Yujian; Park, Shi-Young et al. (2017) Mitochondrial ATP transporter depletion protects mice against liver steatosis and insulin resistance. Nat Commun 8:14477
Mathews, Clayton E; Xue, Song; Posgai, Amanda et al. (2015) Acute Versus Progressive Onset of Diabetes in NOD Mice: Potential Implications for Therapeutic Interventions in Type 1 Diabetes. Diabetes 64:3885-90
Padgett, Lindsey E; Anderson, Brian; Liu, Chao et al. (2015) Loss of NOX-Derived Superoxide Exacerbates Diabetogenic CD4 T-Cell Effector Responses in Type 1 Diabetes. Diabetes 64:4171-83
Gusdon, Aaron M; Fernandez-Bueno, Gabriel A; Wohlgemuth, Stephanie et al. (2015) Respiration and substrate transport rates as well as reactive oxygen species production distinguish mitochondria from brain and liver. BMC Biochem 16:22
Oleson, Bryndon J; McGraw, Jennifer A; Broniowska, Katarzyna A et al. (2015) Distinct differences in the responses of the human pancreatic ?-cell line EndoC-?H1 and human islets to proinflammatory cytokines. Am J Physiol Regul Integr Comp Physiol 309:R525-34
Broniowska, Katarzyna A; Oleson, Bryndon J; McGraw, Jennifer et al. (2015) How the location of superoxide generation influences the ?-cell response to nitric oxide. J Biol Chem 290:7952-60
Chen, Jing; Mathews, Clayton E (2014) Use of chemical probes to detect mitochondrial ROS by flow cytometry and spectrofluorometry. Methods Enzymol 542:223-41
Newby, Brittney N; Terada, Naohiro; Mathews, Clayton E (2014) In search of a surrogate: engineering human beta cell lines for therapy. Trends Endocrinol Metab 25:378-80

Showing the most recent 10 out of 19 publications